home-hero-image-mobile

Vaccine Innovation. Beyond Convention.

We are dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella to protect every child born and every adult at risk across the globe.

See Our Mission
Image for Pushing the Boundaries of What's Possible

Pushing the Boundaries of What’s Possible

Despite widespread vaccination with current pneumococcal conjugate vaccines (PCVs), there is an abundance of non-vaccine strains of the Streptococcus pneumoniae bacteria causing significant morbidity and mortality. This underscores the importance of advancing VAX-24, our lead 24-valent PCV candidate, which is the broadest-spectrum PCV in U.S. clinics today. Upon achieving clinical proof-of-concept, VAX-24 was granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults.

Re-Engineering How Vaccines are Made

We strive to overcome the limitations of conventional, cell-based vaccine approaches using advanced chemistry and modern synthetic techniques – including our XpressCF™ cell-free protein synthesis platform – to produce broad-spectrum vaccines that are uniquely capable of breaking down bacteria’s complex defense mechanisms while preserving immunogenicity.

Image for Pushing the Boundaries of What's Possible

Building a Pipeline of High-Fidelity and Broad-Spectrum Vaccines

Our PCV franchise is intended to improve upon existing pneumococcal vaccines by covering a significant portion of the invasive pneumococcal disease currently in circulation that is associated with high case-fatality rates, antibiotic resistance and meningitis. Following VAX-24, we are developing VAX-31, a 31-valent PCV candidate. Additional vaccine candidates in preclinical development target Group A Strep, periodontitis and Shigella.

Latest News

01

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose by the End of 2025 -- -- VAX-24, a 24-Valent Pneumococcal Conjugate Vaccine (PCV), is Designed to
02

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults -- -- Following VAX-31 Adult
03

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth

Careers: Built to Scale with Purpose

Looking for higher aspirations to ignite your mind and inspire your heart? Then join a team that brings grit and grace to the challenge of protecting every human from the consequences of endemic bacterial infections.